Document is current
Any future updates will be listed below
-
Authors
Merkofer, Franzisca
Struja, Tristan
Delfs, Neele
Spagnuolo, Carlos C.
Hafner, Jason F.
Kupferschmid, Kevin
Baechli, Ciril
Schuetz, Philipp
Mueller, Beat
Blum, Claudine A.
- License Information
-
More Information
Article History
Received: 14 July 2021
Accepted: 7 December 2021
First Online: 5 January 2022
Declarations
:
: The Ethics Committee (EKNZ, Ethics Committee of Northwestern and Central Switzerland) approved the study (No. 2018–01271). Written informed consent from each patient for the use of EHR data for research was granted by January 1st 2018, as required by local legislation. The Ethics Committee approved use of retrospective data for this analysis in the time frame prior to this date.
: N/A
: CAB has received travel funding from Novo Nordisk and participated in an advisory board meeting for Tolvaptan for Otsuka Pharmaceutical Switzerland. All other authors report no copeting interests.
